Cancer-selective targeting of the NF-κB pathway via GADD45β/MKK7 inhibition: Results from the phase I trial of
the first-in-class inhibitor, DTP3, in patients with relapsed or refractory multiple myeloma

OA Location

https://doi.org/10.1182/blood-2025-5825

Author(s)

Chaidos, Aristeidis

Potolidis, Dimitrios

Cornice, Jessica

Auner, Holger

Acton, Gary

more

Type

Conference Paper

Date Issued

2025-11-03

Date Acceptance

2025-10-02

Citation

Blood, 2025, 146 (Suppl. 1), pp.5825-5826

URI

https://hdl.handle.net/10044/1/127510

URL

https://doi.org/10.1182/blood-2025-5825

DOI

10.1182/blood-2025-5825

ISSN

0006-4971

Publisher

American Society of Hematology (ASH Publications)

Start Page

5825

End Page

5826

Journal / Book Title

Blood

Volume

146

Issue

Suppl. 1

Copyright Statement

© 2025 American Society of Hematology. Published by Elsevier Inc. All rights reserved.

Source

67th American Society of Hematology (ASH) Annual Meeting

Publication Status

Published

Start Date

2025-12-05

Coverage Spatial

Orlando, Florida (USA)